ClinicalTrials.gg
CompletedNCT00051987Updated Feb 11, 2008

Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma

A Phase 2 interventional study of VELCADE TM (bortezomib) for Injection, or PS-341 in Colorectal Carcinoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 22 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-02-11.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Colorectal Neoplasms by Takeda — 3 open to participants now, 5 under way, none of them phase 3. Colorectal Neoplasms · Takeda.

Started
2002
with 1 other
Phase 2
4 of 15
none open now
Registered
2nd of 15
by date

Among the 15 studies in Colorectal Neoplasms by Takeda, this one is one of 2 that started in 2002, is one of 4 in phase 2, and was the 2nd registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

3 of the 15 studies in Colorectal Neoplasms by Takeda are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Colorectal Neoplasms by Takeda, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate how tumors in patients with colorectal carcinoma respond to treatment with VELCADE alone versus VELCADE given with irinotecan, and also to see what effects (good and bad) it has on you and your cancer.

Read the detailed description

In this study, patients with colorectal cancer that is no longer responding to standard medical treatment with irinotecan or an irinotecan containing treatment will be randomized to treatment with VELCADE alone or to treatment with VELCADE in combination with irinotecan.

03

Conditions studied

  • Colorectal Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has confirmed inoperable locally advanced or CRC.
  • Patient has .
  • Patient is not considered a candidate for immediate curative resection.
  • Patient has received no more than 2 prior treatment regimens for metastatic disease, one of which must have contained irinotecan.
  • Patient has or progressed while receiving an irinotecan-containing regimen.
  • Patient has of 70% or greater.
  • Patient has a greater than 3 months.
  • Patient is 18 years of age or older.
  • Female patient is , surgically sterilized, or willing to use an acceptable method of (ie, a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.
  • Male patient agrees to use an acceptable method of birth control for the duration of the study.
  • Patient has given voluntary written before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to his or her future medical care.
  • Patient is, in the investigator's opinion, willing and able to comply with the protocol requirements.

Exclusion criteria

Exclusion Criteria

  • Patient has greater than or equal to Grade 2 neuropathy as defined by the NCI Common Toxicity Criteria (CTC):

    • Grade 2: Objective sensory loss or paresthesia (including tingling), interfering with function, but not interfering with activities of daily living (ADL).
    • Grade 3: Sensory loss or paresthesia interfering with ADL.
    • Grade 4: Permanent sensory loss that interferes with function.
  • Patient has previously received treatment with VELCADE.
  • Patient has other except non-melanoma skin cancers and carcinoma of the cervix in situ.
  • Patient has received chemotherapy within 4 weeks prior to enrollment.
  • Patient has received radiation therapy within 4 weeks prior to enrollment.
  • Patient has received monoclonal antibodies within 6 weeks prior to enrollment.
  • Patient had major surgery within 4 weeks prior to enrollment.
  • Patient has inadequate organ function at Baseline (ie, Day 1 of Cycle 1) as defined by the following laboratory values:

    • count ≤ 100,000 x 109/L
    • ≤ 8.0 g/dL
    • (ANC) ≤ 1.5 x 109/L
    • (AST) ≥ 3 times the (ULN)
    • Alanine transaminase (ALT) ≥ 3 times ULN
    • Total ≥ 1.5 times ULN, unless clearly related to the disease
    • Calculated or measured ≤ 60 mL/minute.
  • Patient has had a myocardial infarction within 6 months of enrollment or has New York Hospital Association () Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any (ECG) abnormality at Screening has to be documented by the investigator as not medically relevant.
  • Patient has symptomatic .
  • Patient has an active systemic infection requiring treatment.
  • Patient has a history of inflammatory bowel disease.
  • Patient has a history of allergic reaction attributable to compounds containing boron or mannitol.
  • Patient previously required premature discontinuation of irinotecan therapy because of drug-related toxicity.
  • Patient is known to be (HIV)-positive. Patients assessed by the investigator to be at risk for HIV infection should be tested in accordance with local regulations.
  • Patient is known to be surface antigen-positive or has known active infection. Patients assessed by the investigator to be at risk for hepatitis B or C infection should be tested in accordance with local regulations.
  • Patient has poorly controlled hypertension, diabetes mellitus, or another serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
  • Female patient is pregnant or breast-feeding. Confirmation that the patient is not pregnant must be established by a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test result obtained during the Screening period. Pregnancy testing is not required for or surgically sterilized women.
  • Patient currently is enrolled in another clinical research study or has received an agent for any reason within 4 weeks of enrollment.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
175 participants
06

Study locations

22 sites
  • Cooper Green Hospital / Jefferson Clinic P.C.
    Birmingham, Alabama 35233, United States
  • Arizona Cancer Center
    Tucson, Arizona 85724, United States
  • Arkansas Cancer Center
    Pine Bluff, Arkansas 71603, United States
  • Alta Bates Comprehensive Cancer Center
    Berkley, California 94704, United States
  • California Cancer Center
    Greenbrae, California 94904, United States
  • USC/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • City of Hope Medical Group
    Pasadena, California 91105, United States
  • H. Lee Moffit Cancer Center
    Tampa, Florida 33612, United States
  • Rush Cancer Institute
    Chicago, Illinois 60612, United States
  • Kentuckiana Cancer Institute, PLLC
    Louisville, Kentucky 40202, United States
  • West Michigan Regional Cancer and Blood Center
    Ludington, Michigan 49431, United States
  • Bond Clinic Inc.
    Rolla, Missouri 65402, United States
  • Nevada Cancer Center
    Las Vegas, Nevada 89109, United States
  • Norris Cotton Cancer Center
    Lebanon, New Hampshire 03756, United States
  • The Cancer Institute of New Jersey
    New Brunswick, New Jersey 08901, United States
  • New York University
    New York, New York 10016, United States
  • St. Lukes Rossevelt Hospital
    New York, New York 10019, United States
  • UNC School of Medicine
    Chapel Hill, North Carolina 27599, United States
  • Ohio State University Medical Center
    Columbus, Ohio 43210, United States
  • Oregon Health Sciences
    Portland, Oregon 97201, United States
  • Memphis Cancer Center, PC
    Memphis, Tennessee 38119, United States
  • University of Texas Health Sciences Center at San Antonio
    San Antonio, Texas 78229, United States
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2002 and a primary completion of Mar 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2003
First posted
Jan 22, 2003
Start
Dec 2002
Primary completionActual
Mar 2004
Last update
Feb 11, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00051987
First posted
Jan 22, 2003
Start date
Dec 2002
Primary completion
Mar 2004
Last update
Feb 11, 2008
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bortezomib

Start the discussion